Sfoglia per Rivista JOURNAL OF CLINICAL ONCOLOGY
A Plethora of Therapeutic Opportunities for Elderly Patients With Cancer: A Nontrivial Choice
2016-01-01 Fiorentino, A; Mazzola, R; Giaj Levra, N; Ricchetti, F; Fersino, S; Alongi, F.
Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III
2011-01-01 Pignata, S; Scambia, G; Ferrandina, G; Savarese, A; Sorio, R; Breda, F; Gebbia, V; Musso, P; Frigerio, L; Del Medico, P; Lombardi, Av; Febbraio, A; Scollo, P; Ferro, A; Tamberi, S; Brandes, A; Ravaioli, A; Valerio, Mr; Aitini, E; Natale, D; Scaltriti, L; Greggi, S; Pisano, C; Lorusso, D; Salutari, V; Legge, F; Di Maio, M; Morabito, A; Gallo, C; Perrone, F
Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial
2010-01-01 Pignata, S; Scambia, G; Savarese, A; Sorio, R; Breda, E; Legge, F; Gebbia, V; Musso, P; Gallo, C; Perrone, F on behalf of MITO group
Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a phase II study
2005-01-01 Ferrandina, G; Legge, F; Gallotta, V; Lorusso, D; Testa, Ac; Salutari, V; Paglia, A; Col angelo, M; Fulfaro, F; Scambia, G
Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients
2002-01-01 Ferrandina, G; Lauriola, L; Distefano, Mg; Zannoni, Gf; Gessi, M; Legge, F; Maggiano, N; Mancuso, S; Capelli, A; Scambia, G; Ranelletti, Fo
Personalized--Not Omitted--Radiation Oncology for Breast Cancer
2015-01-01 Fiorentino, A; Mazzola, R; Ricchetti, F; Fersino, S; Giaj Levra, N; Alongi, F.
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer
2006-01-01 Ferrandina, G; Ludovisi, M; D’Agostino, G; Naldini, A; Lorusso, D; Testa, Ac; Legge, F; Salutari, V; Scambia, G
Phase II study on Pemetrexed in advanced and/or recurrent cervical cancer patients: a MITO study
2008-01-01 Ferrandina, G; Lorusso, D; Ludovisi, M; Pignata, S; Sorio, R; Mangili, G; Breda, E; Legge, F; Pisconti, S; Scambia, G
Radical surgery (RS) plus intraperitoneal hyperthermic perfusion (IPHP) with oxaliplatin followed by intravenous docetaxel in the treatment of peritoneal carcinosis from platinum-sensitive recurrent ovarian cancer (OC): A pilot study
2007-01-01 Fagotti, A; Ferrandina, G; Paris, I; Mari, A; Legge, F; Fanfani, F; Facchini, G; Scambia, G
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: No Way Out Without a Randomized Trial? J Clin Oncol. 2018 Aug 20;36(24):2558-2559
2018-01-01 Fiorentino, A; Alongi, F
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A Plethora of Therapeutic Opportunities for Elderly Patients With Cancer: A Nontrivial Choice | 1-gen-2016 | Fiorentino, A; Mazzola, R; Giaj Levra, N; Ricchetti, F; Fersino, S; Alongi, F. | |
| Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III | 1-gen-2011 | Pignata, S; Scambia, G; Ferrandina, G; Savarese, A; Sorio, R; Breda, F; Gebbia, V; Musso, P; Frigerio, L; Del Medico, P; Lombardi, Av; Febbraio, A; Scollo, P; Ferro, A; Tamberi, S; Brandes, A; Ravaioli, A; Valerio, Mr; Aitini, E; Natale, D; Scaltriti, L; Greggi, S; Pisano, C; Lorusso, D; Salutari, V; Legge, F; Di Maio, M; Morabito, A; Gallo, C; Perrone, F | |
| Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial | 1-gen-2010 | Pignata, S; Scambia, G; Savarese, A; Sorio, R; Breda, E; Legge, F; Gebbia, V; Musso, P; Gallo, C; Perrone, F on behalf of MITO group | |
| Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a phase II study | 1-gen-2005 | Ferrandina, G; Legge, F; Gallotta, V; Lorusso, D; Testa, Ac; Salutari, V; Paglia, A; Col angelo, M; Fulfaro, F; Scambia, G | |
| Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients | 1-gen-2002 | Ferrandina, G; Lauriola, L; Distefano, Mg; Zannoni, Gf; Gessi, M; Legge, F; Maggiano, N; Mancuso, S; Capelli, A; Scambia, G; Ranelletti, Fo | |
| Personalized--Not Omitted--Radiation Oncology for Breast Cancer | 1-gen-2015 | Fiorentino, A; Mazzola, R; Ricchetti, F; Fersino, S; Giaj Levra, N; Alongi, F. | |
| Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer | 1-gen-2006 | Ferrandina, G; Ludovisi, M; D’Agostino, G; Naldini, A; Lorusso, D; Testa, Ac; Legge, F; Salutari, V; Scambia, G | |
| Phase II study on Pemetrexed in advanced and/or recurrent cervical cancer patients: a MITO study | 1-gen-2008 | Ferrandina, G; Lorusso, D; Ludovisi, M; Pignata, S; Sorio, R; Mangili, G; Breda, E; Legge, F; Pisconti, S; Scambia, G | |
| Radical surgery (RS) plus intraperitoneal hyperthermic perfusion (IPHP) with oxaliplatin followed by intravenous docetaxel in the treatment of peritoneal carcinosis from platinum-sensitive recurrent ovarian cancer (OC): A pilot study | 1-gen-2007 | Fagotti, A; Ferrandina, G; Paris, I; Mari, A; Legge, F; Fanfani, F; Facchini, G; Scambia, G | |
| Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: No Way Out Without a Randomized Trial? J Clin Oncol. 2018 Aug 20;36(24):2558-2559 | 1-gen-2018 | Fiorentino, A; Alongi, F |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile